Measuring lipoprotein-associated phospholipase A2 (Lp-PLA2) levels has been shown to be useful when predicting adverse cardiac-related events. An increase in Lp-PLA2 levels can predict the development of incident peripheral arterial disease and it has been shown that Lp-PLA2 levels correlate with the incidence of coronary artery disease, stroke and cardiovascular mortality. Recently, the American Heart Association and three other major health organizations have included Lp-PLA2 measurements in their guidelines and listed Lp-PLA2 as a biomarker that is useful for the risk stratification of asymptomatic adult patients.
We provide five in vitro-produced monoclonal antibodies that are specific to human Lp-PLA2. They can be used for the development of quantitative immunoassays which enable the detection of Lp-PLA2 from plasma samples. In addition, we provide recombinant human Lp-PLA2.
Download the Human Lp-PLA2 TechNotes
Cat# 4LA7cc Lipoprotein-associated phospholipase A2 (Lp-PLA2), in vitro, antibody
Cat# 8PL7 Recombinant human lipoprotein-associated phospholipase A2 (Lp-PLA2)